{"id":"W3030929389","doi":"10.1200/jco.2020.38.15_suppl.1006","title":"Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with <i>PIK3CA-</i>mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Fulvestrant; Internal medicine; Metastatic breast cancer; Clinical endpoint; Cohort; Breast cancer; Letrozole; Oncology; Cancer; Clinical trial; Estrogen receptor; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001518398,0.001136063,0.004510754,0.0003889649,0.0002160116,0.00005933292,0.0005694659,0.0006871882,0.0001987375],"category_scores_gemma":[0.001818292,0.0007830786,0.0005120044,0.001127523,0.000920072,0.001204618,0.000177082,0.003626495,0.00002975723],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001735825,"about_ca_system_score_gemma":0.002329931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006431667,"about_ca_topic_score_gemma":0.0009155005,"domain_scores_codex":[0.9878221,0.0019647,0.005802773,0.001508602,0.001732878,0.001168987],"domain_scores_gemma":[0.9880124,0.001665171,0.005297332,0.0005808758,0.00260308,0.001841169],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5402417,0.02708872,0.3020281,0.0001821459,0.003965758,0.004822991,0.007087538,0.0004801276,0.007692686,0.00000677857,0.002406909,0.1039966],"study_design_scores_gemma":[0.1659155,0.1287947,0.6912756,0.001303604,0.00113722,0.0002995976,0.002922974,0.0000242463,0.00624718,0.00001844218,0.0009947314,0.001066181],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842789,0.0003136838,0.00007433689,0.00938916,0.0005155355,0.003637845,0.001546338,0.0001108886,0.0001333122],"genre_scores_gemma":[0.9913601,0.0003412911,0.00273993,0.003242939,0.00165432,0.0001579786,0.0002347789,0.0002076781,0.00006095661],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3892475,"threshold_uncertainty_score":0.999462,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03321510135610873,"score_gpt":0.362653915720541,"score_spread":0.3294388143644323,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}